arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

ArriVent BioPharma, Inc.

AVBP Health Care Biotechnology: Pharmaceutical Preparations
$30.95
Today
as of Sep 4, 16:46 ET
Last 30 days +2.62% Jul 27 → Sep 04
$28.00 $28.94 $29.88 $30.81 $31.75 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$30.79
High
$31.45
Low
$30.59
Volume
$182,374
Avg Vol
$463,821
Mkt Cap
$1.4B
P/E (TTM)
—
Beta
—
52w High
$35.83
52w Low
$17.00
Div Yield
—
Shares Out
$48M

Recent Press Releases & News last 60 days · 1 item

Aug 12 · 20:01 PR GlobeNewswire
ArriVent BioPharma Reports Second Quarter 2026 Financial Results

Overview

52-week range
$17
$36
74% of range
Avg surprise (last 3)
-75.2%
Avg reaction (last 2)
-1.2%
0% positive
Latest IV / EM
148%
EM ±23.2% · $30 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-10.79$-8.24$-5.70$-3.15$-0.61 Actual $-9.45Actual $-10.79Actual $-5.52Actual $-0.70Actual $-0.65Actual $-0.61Actual $-1.90Est $-0.66Actual $-0.90Est $-0.70Actual $-0.83Actual $-0.96Est $-0.88Actual $-1.05 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-64M$-54M$-43M$-32M$-22M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.05 — — — — financials
Mon May 11, 2026Mar/2026 $-0.96 $-0.88 -9.1% +49.5% -1.6% earnings
Tue Sep 30, 2025Sep 2025 $-0.83 — — — — financials
Mon Aug 11, 2025Jun/2025 $-0.90 $-0.70 -28.6% — — earnings
Mon May 12, 2025Mar/2025 $-1.90 $-0.66 -187.9% — -0.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.61 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.65 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.70 — — — — financials
Sat Sep 30, 2023Sep 2023 $-5.52 — — — — financials
Fri Jun 30, 2023Jun 2023 $-10.79 — — — — financials
Fri Mar 31, 2023Mar 2023 $-9.45 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-53M$-46M—$-38M$-34M$-67M—$-24M
Net income$-50M$-43M—$-35M$-31M$-64M—$-21M
EPS (diluted)$-1.05$-0.96—$-0.83$-0.90$-1.90—$-0.61

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$155M$62M$46M$113M$113M$50M$74M$283M
Inventory————————
Total current assets$394M$349M$333M$321M$250M$186M$227M$292M
Total assets$395M$349M$333M$327M$270M$215M$275M$293M
Long-term debt————————
Total liabilities$28M$25M$26M$22M$20M$13M$17M$15M
Total equity$367M$324M$307M$305M$250M$203M$258M$277M

Implied volatility — last 90 days

90%185%280%376%471% Jun 07 — IV 114% · EM ±15.7%Jun 08 — IV 136% · EM ±18.0%Jun 09 — IV 153% · EM ±19.1%Jun 10 — IV 147% · EM ±17.4%Jun 11 — IV 120% · EM ±13.2%Jun 12 — IV 122% · EM ±12.4%Jun 15 — IV 196% · EM ±14.2%Jun 16 — IV 114% · EM ±6.8%Jun 17 — IV 275% · EM ±11.5%Jun 19 — IV 126% · EM ±27.9%Jun 22 — IV 143% · EM ±29.8%Jun 23 — IV 144% · EM ±29.5%Jun 24 — IV 157% · EM ±31.4%Jun 25 — IV 155% · EM ±30.5%Jun 26 — IV 190% · EM ±36.3%Jun 29 — IV 183% · EM ±32.4%Jun 30 — IV 158% · EM ±27.2%Jul 01 — IV 127% · EM ±21.2%Jul 02 — IV 154% · EM ±24.9%Jul 03 — IV 160% · EM ±24.9%Jul 06 — IV 148% · EM ±20.4%Jul 07 — IV 140% · EM ±18.5%Jul 08 — IV 166% · EM ±20.8%Jul 09 — IV 145% · EM ±17.2%Jul 10 — IV 154% · EM ±17.1%Jul 13 — IV 170% · EM ±14.2%Jul 14 — IV 255% · EM ±18.4%Jul 15 — IV 242% · EM ±14.3%Jul 16 — IV 471% · EM ±19.7%Jul 20 — IV 151% · EM ±35.6%Jul 21 — IV 154% · EM ±35.8%Jul 22 — IV 144% · EM ±33.0%Jul 23 — IV 148% · EM ±33.4%Jul 24 — IV 152% · EM ±33.6%Jul 27 — IV 163% · EM ±34.0%Jul 28 — IV 163% · EM ±33.4%Jul 29 — IV 155% · EM ±31.0%Jul 30 — IV 162% · EM ±31.7%Jul 31 — IV 159% · EM ±30.3%Aug 03 — IV 174% · EM ±30.9%Aug 04 — IV 119% · EM ±20.5%Aug 05 — IV 124% · EM ±20.7%Aug 06 — IV 122% · EM ±19.8%Aug 07 — IV 134% · EM ±21.0%Aug 10 — IV 134% · EM ±18.6%Aug 11 — IV 134% · EM ±17.7%Aug 12 — IV 146% · EM ±18.3%Aug 13 — IV 138% · EM ±16.2%Aug 14 — IV 112% · EM ±12.4%Aug 17 — IV 169% · EM ±14.1%Aug 18 — IV 100% · EM ±7.2%Aug 19 — IV 158% · EM ±9.3%Aug 24 — IV 90% · EM ±18.8%Aug 25 — IV 101% · EM ±20.7%Aug 26 — IV 114% · EM ±22.9%Aug 27 — IV 112% · EM ±22.0%Aug 28 — IV 113% · EM ±21.6%Aug 31 — IV 117% · EM ±20.8%Sep 01 — IV 124% · EM ±21.4%Sep 02 — IV 123% · EM ±20.6%Sep 03 — IV 134% · EM ±21.7%Sep 04 — IV 148% · EM ±23.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in